1-6 of 6
Rosalba Martignetti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1867.
https://doi.org/10.1182/blood-2024-205697
Published: 2024
Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation

Clinical Trials & Observations
Anita Kumar, Jacob D. Soumerai, Jeremy S Abramson, Jeffrey A. Barnes, Philip C Caron, Shalini Chhabra, Maria Chabowska, Ahmet Dogan, Lorenzo Falchi, Clare Grieve, J. Erika Haydu, Patrick Connor Johnson, Ashlee Joseph, Hailey Kelly, Alyssa Labarre, Jennifer K Lue, Rosalba Martignetti, Joanna Mi, Alison J Moskowitz, Colette N Owens, Sean Plummer, Madeline Puccio, Gilles A. Salles, Venkatraman E Seshan, Elizabeth Simkins, Natalie Slupe, Honglei Zhang, Andrew D. Zelenetz
Journal: Blood
Blood blood.2024025563.
https://doi.org/10.1182/blood.2024025563
Published: 2024
Includes: Supplemental data
Journal Articles

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Anita Kumar, Jacob Soumerai, Jeremy S. Abramson, Jeffrey A. Barnes, Philip Caron, Maria Chabowska, Mary Devlin, Ahmet Dogan, Lorenzo Falchi, Rayna N. Garcia, Clare Grieve, Emma Haskell, Julie E. Haydu, Patrick Connor Johnson, Ashlee Joseph, Hailey E. Kelly, Alyssa Labarre, Emerald D Littlejohn, Jennifer Kimberly Lue, Joanna Mi, Rosalba Martignetti, Grace McCambridge, Alison Moskowitz, Colette Owens, Sean F. Plummer, Madeline G. Puccio, Gilles Salles, Venkatraman Seshan, Natalie Slupe, Andrew D. Zelenetz
Journal: Blood
Blood (2023) 142 (Supplement 1): 738.
https://doi.org/10.1182/blood-2023-180069
Published: 2023
Journal Articles

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

Anita Kumar, Jacob D. Soumerai, Jeremy S. Abramson, Connie Lee Batlevi, Puja Chadha, Ahmet Dogan, Lorenzo Falchi, Kelsey Flaherty, Chaya Friedman, Clare Grieve, Caleb Ho, P. Connor Johnson, Ashlee Joseph, Niloufer Khan, Joanna Mi, Rosalba Martignetti, Matthew J. Matasar, Colette Owens, Jade Ruiters, Sidney Sechio, Venkatraman Seshan, Elizabeth Simkins, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 138 (Supplement 1): 3540.
https://doi.org/10.1182/blood-2021-151831
Published: 2021
Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Jacob D. Soumerai, Anthony R. Mato, Ahmet Dogan, Venkatraman Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim P Hochberg, Jeffrey A Barnes, Audrey Hamilton, Jeremy S. Abramson, Connie Lee Batlevi, Matthew J. Matasar, Ariela Noy, Colette Owens, M. Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma, Chaya Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, Natascha Nolet, Neena Mahajan, Rosalba Martignetti, Joanna Mi, Krista J Scorsune, Julia M Lynch, Brianne McGree, Stephanie Y Hughes, Clare Grieve, Lindsey E. Roeker, Meghan C. Thompson, P. Connor Johnson, Mikhail Roshal, Jane Huang, Juliana M.L. Biondo, Jenny Qun Wu, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 138 (Supplement 1): 3753.
https://doi.org/10.1182/blood-2021-150961
Published: 2021
Journal Articles

A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

Lindsey E. Roeker, Lori A. Leslie, Jake D. Soumerai, Victoria Falco, Gail Panton, Andrew D. Zelenetz, Lorenzo Falchi, Jae H Park, Camila Pena-Velasquez, Sonia Lebowitz, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, David J. Straus, Yehudit Fox, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Hari P. Miskin, Peter Sportelli, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 395.
https://doi.org/10.1182/blood-2021-146999
Published: 2021